Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready
Fusion Pharmaceuticals Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The portfolio involves 4 distinct examiners and 2 distinct art units, indicating both examiner overlap and concentration within the art-unit assignments.
MOSHER, ERIC PARKER is the busiest examiner, with 2 pending matters. Counsel should coordinate the matters assigned to that examiner while preserving separate analyses for the remaining applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 2 (40%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSHER, ERIC PARKER | 2 | 100.0% | +0.0% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| DICKINSON, PAUL W | 1 | 63.2% | +9.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833849 | NTSR1-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | MOSHER, ERIC PARKER | — |
| 18703995 | METHODS OF TREATING CANCER | MOSHER, ERIC PARKER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18541618 | COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX | DICKINSON, PAUL W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833850 | PSMA-TARGETED RADIOPHARMACEUTICALS AND CHECKPOINT INHIBITOR COMBINATION THERAPY | CRAIG, KAILA ANGELIQUE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 3 |
| 1612 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833850 | PSMA-TARGETED RADIOPHARMACEUTICALS AND CHECKPOINT INHIBITOR COMBINATION THERAPY | CRAIG, KAILA ANGELIQUE | 1618 | §103Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18833849 | NTSR1-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | MOSHER, ERIC PARKER | 1612 | §103§112DP | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18703995 | METHODS OF TREATING CANCER | MOSHER, ERIC PARKER | 1612 | §103§112DP | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18541584 | COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND AND FOLFIRINOX | BAEK, JONGHWAN NMN | 1618 | §103Other | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18541618 | COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX | DICKINSON, PAUL W | 1618 | §101§103DP | Non-Final OA | — | Pending | Dec 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFusion Pharmaceuticals Inc. has 5 pending office actions as of October 2026, spread across 2 art units and 4 examiners.
Eric Parker Mosher has the most, with 2 of Fusion Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
